Consistent with current practice, ruxolitinib was not incorporated into frontline induction for Ph-like ALL; outside clinical trials, NCCN emphasizes ABL-class TKIs (e.g., dasatinib) when an ABL-class lesion is present, whereas JAK-pathway inhibition is investigational (e.g., ruxolitinib in COG AALL1521 and other early-phase studies) [19–21]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.